《大行報告》大摩微升新秀麗(001910.HK)目標價至35元 料管理層對前景更有信心
摩根士丹利發表報告指,新秀麗(01910.HK)股價自2月26日起上升21%,同期恆指只升1%,主要因為媒體報道公司接獲收購建議。即使股價上升後,但估值較全球同業仍有折讓,相信出行需求增長支持其銷售前景,旗下Tumi及亞洲市場的增長將會推升其利潤率。近期旅遊行業數據令人鼓舞,該行估計新秀麗管理層在未來公布業績時,會發表更確信的前景展望。
該行估計新秀麗今明兩年銷售增長分別9%及7%,目標價由34.3元上調至35元,評級「增持」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.